a 12 year old with liver disease and pulmonary
play

A 12 Year Old with Liver Disease and Pulmonary Hypertension Russel Hirsch, M.D. The Heart Institute Cincinnati Childrens Hospital Medical Center X X X X X X X X 0 Unanticipated consequences Ethical dilemmas Issues of

0 downloads 2 Views 1,06 MB Size Report
  1. A 12 Year Old with Liver Disease and Pulmonary Hypertension Russel Hirsch, M.D. The Heart Institute Cincinnati Children’s Hospital Medical Center

  2. X X X X X X X X 0

  3. • Unanticipated consequences • Ethical dilemmas • Issues of autonomy • Family / Care team trust issue • Multi-system complexity • Extreme resource allocation • Logistic considerations • Unfortunate outcomes • ? Paternalism

  4. KH, 12 year old female Clinical Presentation • Asymptomatic, normal activities – Competitive basketball player / Horse (barrel) racing • Cleaning horse stall and kicked in the belly • ER evaluation with severe abdominal pain / hematuria • MRI – Renal contusion – Multiple hepatic lesions (AVM vs. hepatic nodules) – Dilated IVC • No cardiac symptoms Examination • BP132/60 • Classic signs of RVH and PH – Sternal heave / Palpable 2 nd heart sound, Loud, wide split S2 • 3cm hepatomegaly, mild tenderness

  5. KH: Baseline Studies

  6. KH: Baseline Echo Images

  7. KH: Baseline Echo Images

  8. KH: Baseline MRI Images

  9. KH: Baseline CC BL iNO 80ppm / 30% FiO2 80% FiO2 Rp 9.1 9.8 Rs 13.5 CI 5.4 3.68 Mean PA 52 50 Pressure Mean RA 7 Pressure

  10. KH: Course • Open liver biopsy during cardiac catheterization, and hepatic vein injections – Focal nodular hyperplasia High likelihood of malignant potential – Portal venous malformation with Abernathy- type physiology

  11. Family Discussion • Offered liver transplantation – Declined • Agreed to commence vaso-dilator therapy to maintain a transplantable state – Plan for frequent reassessment

  12. KH: Course • Medications commenced as out-patient – Oral Sildenafil – Inhaled treprostinil • Dose increased gradually to maximum of 9 breaths q4h • Occasional dizziness – Bosentan contra-indicated • Exercise restriction Follow-Up at 3 Months • Asymptomatic • Compliant • Liver transplant evaluation in progress – Family reticent

  13. KH: Follow-Up Cath: 3 months BL iNO Follow-Up 30% 80ppm (3 FiO2 / FiO2 months) 80% Rp 9.1 9.8 4.95 Rs 13.5 11.73 CI 5.4 3.68 5.45 Mean PA 52 50 42 Pressure Mean RA 7 7 Pressure

  14. Continued Follow-Up • Maintained on Sildenafil and inhaled treprostinil • Active / asymptomatic • Repeat cath 5 months post presentation, continued stability • 9 months post presentation – Mild peripheral edema – Exertional dyspnea – Low Albumin

  15. BL 3 months 9 month Rp 9.1 4.95 7.7 Rs 13.5 11.73 14 CI 5.4 5.4 4.9 Mean PA 52 42 52 Pressure Mean RA 7 7 9 Pressure Sildenafil and Inhaled Treprostinil

  16. Therapeutic Intervention • Tunneled central line placed from right subclavian vein into the SVC • Converted from inhaled to continuous IV treprostinil • No further discussion about liver transplantation • Gradual up-titration of treprostinil as out-patient • Follow-Up Cath at 7 month after conversion to IV therapy – No change in PA pressures or Rp despite substantial up-titration

  17. Clinical Change: 18 months post presentation (2 months after last cath) • One month history – Low grade fever – 6kg weight loss – Intermittent nausea / occasional vomiting • Exam – Lethargic – Swollen / edematous – Harsh 3/ holosystolic murmur

  18. Blood Cultures: Positive for Streptococcus mitis

  19. • Severe TR • Estimated RV pressure 95mmHg by TR Doppler velocity

  20. • Severe TR • Estimated RV pressure 95mmHg by TR Doppler velocity

  21. • Severe TR • Estimated RV pressure 95mmHg by TR Doppler velocity

  22. Clinical Dilemma • Active endocarditis / severe TR / Severe CHF / Severe PH – Unlikely to survive surgery without mechanical support • No longer liver transplantable – Severe PH ……….unless…..

  23. “Only” way out • Perform tricuspid valve replacement • Support with ECMO / conversion to Lung Assist Device • List for lung and liver transplantation ………..family declined, and requested discharge as soon as possible….

  24. Hospital Course • Broviac removed – PICC inserted • D/C on antibiotics / Lasix / Continued Remodulin • Hospice contacted and involved

  25. Out-Patient Course • Slow decline – Moderate facial and peripheral edema – Sedentary • Blood culture negative at 6 weeks and d/c antibiotics Clinic Visit at 3 months • Persistent edema • Comfortable • Exercise capacity stable • No echo / persistent clinical signs of PH

  26. Clinic visit at 6 months • Remarkably better!!! • Active, back at school full-time • No edema • Signs of PH minimal • Echo – Severe TR with dilated RA – Estimated RV pressure 40-50mmHg Conversion to Oral Treprostinil • 10 months post endocarditis • PICC line removed • Cath with stable hemodynamics – Lower CI – Higher SVR

  27. BL 5 week 9 month 39 months Rp 9.1 4.95 7.7 6.2 Rs 13.5 11.73 14 23 CI 5.4 5.4 4.9 3.2 Mean PA 52 42 52 37 Pressure Mean RA 7 7 9 7 Pressure Parents still declined any further aggressive therapies, and no discussion of organ transplantation

  28. Clinic Follow-Up – 4 months later • Poor appetite • Occasional vomiting • Intermittent belly pain • Cardiac exam: Unchanged / Edematous • Large, tender mobile mass in the epigastrium • Echo with worse PH • MRI of the belly…….

  29. KH: Baseline MRI Images

  30. • Massive enlargement of liver masses / sub-capsular position • Heterogeneous consistency • Unclear if malignant conversion

  31. Subsequent Course • 6 months later, after horse race – Severe belly pain • ER evaluation with distended and acute abdomen, clinically in shock • Resuscitated and CT with free fluid (blood) in abdomen • Expired 2 hours later

  32. Care for this patient: It takes a village (and a hospital)! • Cath Lab and Cath Lab Recovery (8 caths) • Echo lab (31 studies) • PH Service – Michelle Cash, Melissa Magness, Susan Hoelle • CICU / In-patient Cardiology Service • Liver Service • Infectious Disease Service • Ethics Service • Radiology (4 MRI’s / 1 CT / Uncountable CXR’s) • Lab (29 CBC / 33 renal panels, etc.etc.)

  33. Most Importantly…….. • Complexity of care – Family demands – Religious and social influences – Ethical considerations – Resource allocation …….in addition to the medical issues

  34. Thank You!

  35. Portal Pulmonary Hypertension – Possible Mechanisms • Imbalance of vasoconstrictive and vasodilatory mediators – Serotoinin, interlekin-1, endothelin -1, glucagon, secretin, thromboxane B2, etc. • Genetic predisposition • Thromboembolism from the portal venous circulation • Hyperdynamic pulmonary circulation • Inflammation – Elevated cytokines in cirrhosis

  36. Survival: Portal Pulmonary Hypertension • REVEAL Registry data* • 5 yr survival 40% in subjects with PoPH versus 64% IPAH/FPAH • Review of Mayo Data (1994-2007)** • 74 PoPH patients • No treatment (19 pts): 5 yr survival 14% • Pulm Vaso-dilator (43 pts): 5 yr survival 45% • Liver Transplantation*** • mPAP > 50mmHg - 100% liver transplant mortality • mPAP < 35mmHg – 100% liver transplant survival * Krowka et.al. Chest 2012;141:906-915 **Swanson et.al. AmJTransplant 2008;8:2445-2453 ***Krowka et.al.Liver Transpl 2000;6:443-450

Recommend Documents


pulmonary vasculopathies
Pulmonary vasculopathies: 1.2.1 BMPR2

4/21/2018 5TH WORLD SYMPOSIUM CLASSIFICATION OF PH 1. PULMONARY ARTERIAL

liver cancer in hiv
Liver cancer in HIV David Wong, MD

Liver cancer in HIV David Wong, MD Toronto Centre for Liver Disease TGH

live donor liver transplantation a life saving option for
Live Donor Liver Transplantation: A

March 12, 2019 Live Donor Liver Transplantation: A Life Saving Option for End

fatty liver disease
Fatty Liver Disease NASH-NAFLD with

5/23/2014 Definitions NAFLD Fat in the liver (imaging or histology) in a

pulmonary disease
PULMONARY DISEASE INCIDENCE UP TO

CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN

liver disease in women
Liver Disease in Women: Evaluation of

Disclosures Liver Disease in Women: Evaluation of Abnormal Liver Tests None

effects of liver disease on pharmacokinetics
Effects of Liver Disease on

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D.

surgery for pulmonary ntm disease
Surgery for Pulmonary NTM Disease r e

Surgery for Pulmonary NTM Disease r e t n n e o s i t e c r u P

genetics of alcoholic liver disease
Genetics of alcoholic liver disease

25th Annual Meeting HKASLD, November 18th, 2012, Hong Kong Genetics of

diabetes management in liver and kidney disease
Diabetes management in liver and kidney

4/12/2018 Diabetes management in liver and kidney disease Epidemiology 1

improving the biophysical activity of dysfunctional lung
Improving the Biophysical Activity of

Improving the Biophysical Activity of Dysfunctional Lung Surfactant Vanessa

intercept 1q16 earnings presentation
Intercept 1Q16 Earnings Presentation

Intercept 1Q16 Earnings Presentation May 5 th , 2016 Safe Harbor Statement

medical management of high output
Medical management of high output

Oxford Inflammatory Bowel Disease MasterClass Medical management of high

chemical biology of tea catechins
Chemical Biology of Tea Catechins

Workshop Argentina-Japan Bioscience and Biotechnology for the Promotion of

pot otentia ial l trial d des esigns s and suitable e
Pot otentia ial l trial d des

Pot otentia ial l trial d des esigns s and suitable e study populati

a detailed look at impurities in medicines
A detailed look at impurities in

A detailed look at impurities in medicines Dr John Churchill Principal

systemic lupus erythematosus presentjng as acute adrenal
Systemic Lupus Erythematosus Presentjng

[Downloaded free from http://www.amhsr.org] Case Report Systemic Lupus

make it count
Make it count Technical considerations

Make it count Technical considerations and initial findings for accurate

submit
SUBMIT Cas ase P e Presen entat

SUBMIT Cas ase P e Presen entat ation COVID-19 Kurt DeVine, MD and

glycocalyx loss
Glycocalyx Loss Podocyte and Kidney

Glycocalyx Loss Podocyte and Kidney Injury Induces Albuminuria Nat Rev

management of management of hypertension hypertension
Management of Management of

Management of Management of Hypertension Hypertension M Misra MD MRCP (UK)

dine amp learn roundtable ckd what to expect
Dine & Learn Roundtable CKD What

Dine & Learn Roundtable CKD What to Expect Dr. Caroline Stigant April 30,